| General Information | |
|---|---|
| ZINC ID | ZINC000040939398 |
| Molecular Weight (Da) | 404 |
| SMILES | O=C(NN1CCCCC1)c1ccc2c(c1)N=C(C1CCCCC1)c1ccccc1O2 |
| Molecular Formula | C25N3O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 118.79 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 30 |
| LogP | 5.504 |
| Activity (Ki) in nM | 79.4328 |
| Polar Surface Area (PSA) | 53.93 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.062 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.44 |
| Ilogp | 3.73 |
| Xlogp3 | 5.37 |
| Wlogp | 4.86 |
| Mlogp | 4.11 |
| Silicos-it log p | 4.76 |
| Consensus log p | 4.57 |
| Esol log s | -5.76 |
| Esol solubility (mg/ml) | 0.000706 |
| Esol solubility (mol/l) | 0.00000175 |
| Esol class | Moderately |
| Ali log s | -6.26 |
| Ali solubility (mg/ml) | 0.000224 |
| Ali solubility (mol/l) | 0.00000055 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.04 |
| Silicos-it solubility (mg/ml) | 0.0000368 |
| Silicos-it solubility (mol/l) | 9.12E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.95 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.15 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.718 |
| Logd | 4.118 |
| Logp | 5.126 |
| F (20%) | 0.049 |
| F (30%) | 0.019 |
| Mdck | - |
| Ppb | 98.71% |
| Vdss | 0.859 |
| Fu | 0.67% |
| Cyp1a2-inh | 0.141 |
| Cyp1a2-sub | 0.923 |
| Cyp2c19-inh | 0.751 |
| Cyp2c19-sub | 0.572 |
| Cl | 1.597 |
| T12 | 0.071 |
| H-ht | 0.375 |
| Dili | 0.882 |
| Roa | 0.815 |
| Fdamdd | 0.369 |
| Skinsen | 0.811 |
| Ec | 0.003 |
| Ei | 0.013 |
| Respiratory | 0.958 |
| Bcf | 1.749 |
| Igc50 | 5.182 |
| Lc50 | 5.386 |
| Lc50dm | 5.362 |
| Nr-ar | 0.043 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.906 |
| Nr-aromatase | 0.934 |
| Nr-er | 0.654 |
| Nr-er-lbd | 0.023 |
| Nr-ppar-gamma | 0.922 |
| Sr-are | 0.854 |
| Sr-atad5 | 0.124 |
| Sr-hse | 0.86 |
| Sr-mmp | 0.955 |
| Sr-p53 | 0.795 |
| Vol | 427.653 |
| Dense | 0.943 |
| Flex | 0.133 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.723 |
| Synth | 2.619 |
| Fsp3 | 0.44 |
| Mce-18 | 62.667 |
| Natural product-likeness | -0.658 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |